Search Results - "Perkins, Edward B"

A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-cell Lymphoma by Yazbeck, Victor, Shafer, Danielle, Perkins, Edward B., Coppola, Domenico, Sokol, Lubomir, Richards, Kristy L., Shea, Thomas, Ruan, Jia, Parekh, Samir, Strair, Roger, Flowers, Christopher, Morgan, David, Kmieciak, Maciej, Bose, Prithviraj, Kimball, Amy, Badros, Ashraf Z., Baz, Rachid, Lin, Hui-Yi, Zhao, Xiuhua, Reich, Richard R., Tombes, Mary Beth, Shrader, Ellen, Sankala, Heidi, Roberts, John D., Sullivan, Daniel, Grant, Steven, Holkova, Beata

“…Patients with relapsed/refractory non-Hodgkin lymphoma remain a population with an unmet medical need. Histone deacetylase inhibitors and proteasome inhibitors…”
Get full text

Phase I trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl+ hematological malignancies by Bose, Prithviraj, Perkins, Edward B., Honeycut, Connie, Wellons, Martha D., Stefan, Tammy, Jacobberger, James W., Kontopodis, Emmanouil, Beumer, Jan H., Egorin, Merrill J., Imamura, Chiyo K., Douglas Figg, W., Karp, Judith E., Koc, Omer N., Cooper, Brenda W., Luger, Selina M., Colevas, A. Dimitrios, Roberts, John D., Grant, Steven

“…Purpose Imatinib is an inhibitor of the Bcr-Abl tyrosine kinase; however, resistance is common. Flavopiridol, a cyclin-dependent kinase (CDK) inhibitor,…”
Get full text

Venetoclax and Cytarabine in AML Transformed from Myelofibrosis by McKay, John, Gayhart, Matthew, Al-Juhaishi, Taha, Yazbeck, Victor, Perkins, Edward B.

“…Background Acute myeloid leukemia (AML) accounts for 1% of all newly diagnosed cancers with a mean age at diagnosis of 68. Although the majority present de…”
Get full text

Two Homologous Enhancer Elements in the Chicken Vimentin Gene May Bind a Nuclear Factor in Common with a Nearby Silencer Element (∗) by Perkins, Edward B., Cunningham, Janet G., Bracete, Alma M., Zehner, Zendra E.

“…Vimentin, a cytoskeletal protein belonging to the intermediate filament protein family, exhibits a complex pattern of expression. In the case of the chicken…”
Get full text

Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory Indolent B-Cell Neoplasms - Update of the “Bolus” Infusion Schedule of Alvocidib by Holkova, Beata, Perkins, Edward B., Bose, Prithviraj, Sullivan, Daniel M, Baz, Rachid, Tombes, Mary Beth, Shrader, Ellen, Ramakrishnan, Viswanathan, Wan, Wen, Sankala, Heidi, Kmieciak, Maciej, Roberts, John D., Grant, Steven

“…Abstract 2959 Preclinical studies suggest that neoplastic cells may be particularly sensitive to simultaneous interruption of cell cycle and survival signaling…”
Get full text

A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-Cell Lymphoma by Holkova, Beata, Perkins, Edward B., Sokol, Lubomir, Richards, Kristy L., Parekh, Samir, Elstrom, Rebecca, Badros, Ashraf Z., Espinoza-Delgado, Igor, Schell, Michael J., Kimball, Amy, Tombes, Mary Beth, Shrader, Ellen, Sankala, Heidi, Coppola, Domenico, Kmieciak, Maciej, Sullivan, Daniel, Roberts, John D., Grant, Steven

“…Abstract 779▪FN2▪This icon denotes a clinically relevant abstract Numerous preclinical studies have demonstrated synergistic interactions between proteasome…”
Get full text

Phase I trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl^sup +^ hematological malignancies by Bose, Prithviraj, Perkins, Edward B, Honeycut, Connie, Wellons, Martha D, Stefan, Tammy, Jacobberger, James W, Kontopodis, Emmanouil, Beumer, Jan H, Egorin, Merrill J, Imamura, Chiyo K, Douglas Figg, W, Karp, Judith E, Koc, Omer N, Cooper, Brenda W, Luger, Selina M, Colevas, A Dimitrios, Roberts, John D, Grant, Steven

“…Imatinib is an inhibitor of the Bcr-Abl tyrosine kinase; however, resistance is common. Flavopiridol, a cyclin-dependent kinase (CDK) inhibitor, down-regulates…”
Get full text

Phase I Trial of Bortezomib (NSC 681239) and Flavopiridol (NSC 649890) in Patients with Recurrent or Refractory Indolent B-Cell Neoplasms by Grant, Steven, Sullivan, Daniel, Roodman, David, Stuart, Robert, Perkins, Edward B., Ramakrishnan, Viswanathan, Wright, John, Colevas, A. Dimitrios, Roberts, John D.

“…Preclinical studies suggest that neoplastic cells may be particularly sensitive to simultaneous interruption of cell-cycle and survival signaling pathways. In…”
Get full text

Phase I Study of Flavopiridol in Combination with Imatinib Mesylate (STI571, Gleevec) in Bcr/Abl+ Hematological Malignancies by Grant, Steven, Karp, Judith E., Koc, Omer N., Cooper, Brenda, Luger, Selina, Figg, William D., Egorin, Merrill, Druker, Brian J., Jacobberger, James W., Ramakrishnan, Viswanathan, Perkins, Edward B., Colevas, A. Dimitrios, Roberts, John D.

“…Imatinib (Im), a rationally designed inhibitor of the Bcr/Abl kinase as well as other kinases, represents the standard treatment for Bcr/Abl+ malignancies. Im…”
Get full text